BardyDx Carnation Ambulatory Monitor (CAM™) – P-wave centric™ ambulatory cardiac patch monitoring and arrhythmia detection
Bardy Diagnostics announced that it appointed Kevin Hykes as its new president, CEO and member of its board effective Aug. 31, 2020.
Hykes has more than 28 years of experience in the medical device industry, having served as president and CEO of Relievant Medical Systems, Metavention and Cameron Health. Additionally, Hykes held roles as an operating partner at Revival Healthcare Capital and Versant Ventures, having previously held leadership positions at Medtronic, too.
His role includes responsibilities for leading the development and execution of short-term and long-term business and financial strategies while managing the overall operations of Bardy, according to a news release.
“I’m very excited and pleased to have Kevin join our executive team as President and CEO,” Bardy founder & chairman Dr. Gust Bardy said in the release. “I’ve had the privilege of working with Kevin when he was CEO of the last company I founded, Cameron Health, where he led the global commercialization of the subcutaneous implantable cardioverter defibrillator and ultimately our successful sale to Boston Scientific.
“I am looking forward to transitioning into my new role as chief medical officer and chief innovation officer and turning day-to-day management of the company over to Kevin as we continue to experience tremendous growth in the adoption of our CAM p-wave centric patch as the new standard of care in ambulatory cardiac monitoring devices.”
Bardy has developed the CAM (Carnation ambulatory monitor) for monitoring cardiac rhythms, most recently winning CE Mark approval for a new patch that gives clinicians more flexibility to monitor patients over a longer period of time while expanding the portfolio of the company’s existing 2-day and 7-day CAM patches.
“It’s an honor to join the outstanding team at Bardy Diagnostics and to build upon the significant momentum that the company has established in the marketplace with its best in class ambulatory ECG monitoring and analysis technology,” Hykes said. “The demonstrated clinical superiority of Bardy Diagnostics’ p-wave centric technology uniquely positions the company to capitalize on the growing interest in remote patient monitoring for patients with chronic health conditions.”